Organisation paid for research Program year 2024 Source: CMS Open Payments

Bioclinica Inc

Neither a doctor nor a teaching hospital

Research payments

$6,988,500

736 payments

Through program year 2024, Bioclinica Inc is reported as receiving $6,988,500 in research payments, across 736 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2024	Research	$170,105	44
2023	Research	$2,660,831	346
2022	Research	$3,247,976	187
2021	Research	$799,161	101
2020	Research	$109,957	54
2019	Research	$470	4

Breakdown

Who paid Research payments · program years 2019–2024

GlaxoSmithKline, LLC. $6,857,294 683 payments
Ge Healthcare $103,787 50 payments
Eli Lilly and Company $23,939 1 payment
Guerbet LLC $3,480 2 payments

Studies the money was for Research payments · program years 2019–2024

A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Thera $3,914,532 248 payments
Dreamm 7: A Multicenter, Open-Label, Randomized Phase III Study to Eva $970,400 1 payment
A Randomized, Phase 2, Double-Blind Study to Evaluate the Efficacy of $554,136 98 payments
A Randomised, Double-Blind, Parallel Group Phase III Study to Assess T $492,487 106 payments
A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarl $341,190 65 payments
Master Protocol to Assess the Safety and Antitumor Activity of Genetic $206,218 92 payments
A Phase 2, Randomized, Open-Label, Platform Study Utilizing A Master P $134,714 16 payments
A Randomised, Double-Blind, Placebo Controlled, Parallel Group Phase I $109,670 31 payments
A Phase 3| Open Label| Multicenter Study of Flurpiridaz (18F) Injection for Positive Emission Tomography (PET) Imaging $103,787 50 payments
Tumor Growth Kinetics in Patients With Solid Tumors $57,120 4 payments

What the money was spent on Research payments · program years 2019–2024

Other $3,480 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.